News

The Shanghai Canbi news column provides information on reference preparations, pharmaceutical intermediates, development of pharmaceutical raw materials and blood products in the field of biomedicine. Access to the latest and most comprehensive medical news policies through various global medical news platforms, collect the latest medical research and development data, take you to understand the latest trends and policies of the pharmaceutical industry, stay at home to read the latest global medical news and information.

• 
  Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy
  Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibit
  Tags：
  The number of readers：928
  Source：
  2021-06-29
• 
  Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer
  Sandoz today announced the launch of generic oncology treatment Pemetrexed in 11 countries across Europe, including Germany, Switzerland, Netherlands, and Spain.
  Tags：
  The number of readers：915
  Source：
  2021-06-25
• 
  FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ra
  Tags：
  The number of readers：925
  Source：
  2021-06-24
• 
  China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has granted its anti-PD-1 an
  Tags：
  The number of readers：929
  Source：
  2021-06-23
• 
  FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children
  Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have b
  Tags：
  The number of readers：905
  Source：
  2021-06-22
• 
  Health Canada Grants Marketing Authorization for TRIKAFTA® in People Ages 12 and Older Who Have at Least One F508del Mutation
  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and olde
  Tags：
  The number of readers：883
  Source：
  2021-06-19
• 
  FDA Approves Astepro® Allergy Nasal Spray for Over-the-Counter Use in the United States
  Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Astepro® Allergy (Azelastine HCI .15%) as an over-the-counter (OTC) product for the temporary relief of nasal congestion, runny nose, sneezing and itchy nose due to hay f
  Tags：
  The number of readers：866
  Source：
  2021-06-18
• 
  FDA Approves Rezipres (ephedrine hydrochloride injection) for Hypotension During Anesthesia
  Eton Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
  Tags：
  The number of readers：894
  Source：
  2021-06-16
• 
  New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)
  Roche today announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously
  Tags：
  The number of readers：876
  Source：
  2021-06-11
• 
  Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
  Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissue
  Tags：
  The number of readers：875
  Source：
  2021-06-09

Product Info

Product Name

Synonyms

CAS

Molecular Formula Upload

Contact Us

Company

Name

Tel

Email

Details

Submit

• Please fill in product name !
• CAS
• Please fill in your company information correctly!
• Please fill in liaison information correctly!
• Please fill in your telephone number correctly!
• Please fill in your email correctly!
• Please describe the problem of products!